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Abstract
Background Se-methylselenocysteine (MSC) is a naturally
occurring organoselenium compound that inhibits mammary
tumorigenesis in laboratory animals and in cell culture models.
Previously we have documented that MSC inhibits DNA
synthesis, total protein kinase C and cyclin-dependent kinase 2
kinase activities, leading to prolonged S-phase arrest and
elevation of growth-arrested DNA damage genes, followed by
caspase activation and apoptosis in a synchronized TM6 mouse
mammary tumor model. The aim of the present study was to
examine the efficacy of MSC against TM6 mouse mammary
hyperplastic outgrowth (TM6-HOG) and to determine in vivo
targets of MSC in this model system.
Methods Twenty mammary fat pads each from female Balb/c
mice transplanted with TM6-HOG and fed with 0.1 ppm
selenium and with 3 ppm selenium respectively, were evaluated
at 4 and 12 weeks after transplantation for growth spread,
proliferative index and caspase-3 activity. Thirteen mice
transplanted with TM6-HOG in each selenium group were
observed for tumor formation over 23 weeks. Tumors from mice
in both groups were compared by cDNA array analysis and data
were confirmed by reverse transcription–polymerase chain
reaction. To determine the effect of MSC on the expression of
the novel target gene and on cell migration, experiments were
performed in triplicate.
Results A dietary dose of 3 ppm selenium significantly reduced
the growth spread and induced caspase-3 activity in mammary
fat pads in comparison with mice fed with the basal diet (0.1
ppm selenium). The extended administration (23 weeks) of 3
ppm selenium in the diet resulted in a tumor incidence of 77%
in comparison with 100% tumor incidence in 0.1 ppm selenium-
fed animals. The size of TM6 tumors in the supplemented group
was smaller (mean 0.69 cm2) than in the mice fed with the basal
diet (mean 0.93 cm2). cDNA array analysis showed a reduced
expression of osteopontin (OPN) in mammary tumors of mice
fed with the 3 ppm selenium diet in comparison with OPN
expression in tumors arising in 0.1 ppm selenium-fed mice. A
24-hour treatment of TM6 cells with MSC significantly inhibited
their migration and also reduced their OPN  expression in
comparison with untreated cells.
Conclusions OPN is a potential target gene in the inhibition of
mammary tumorigenesis by selenium.
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Introduction
Se-methylselenocysteine (MSC) is a component of selen-
ized brewer's yeast that has been successfully used to
reduce overall cancer mortality by more than 40% in a
human clinical intervention [1]. Specifically, this selenized
yeast was composed of selenomethionine (more than
85%), with components such as MSC, selenocystathione,
selenocystine and other unidentified organic selenium
compounds forming the remainder [2]. MSC suppresses
carcinogen-induced mammary carcinogenesis in rat model
[3,4], in which it enhances the fraction of p27Kip1-positive
cells in mammary intraductal proliferations [5]. In vitro,
MSC is an effective growth inhibitor of mammary cells
[6,7]. We have shown in a synchronized TM6 mouse mam-
mary tumor cell model that MSC inhibits DNA synthesis
and total protein kinase C activity, causes S-phase arrest of
these cells, reduces cyclin-dependent kinase 2 kinase
activity, and induces growth-arrested DNA damage genes
[7,8]. In the same model system MSC also activated cas-
pase-3 and induced apoptosis [9]. More recently, we have
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documented the inhibition of phosphatidylinositol 3-kinase
activity followed by dephosphorylation of Akt by MSC in
mouse mammary cells in vitro [10].
To identify potential targets of MSC in vivo, we used the
cDNA array approach to compare gene expression profiles
in the tumors arising from the mammary fat pads of mice fed
on a diet high in selenium (3 ppm Se as MSC) with those
in tumors from mice fed on the basal diet (0.1 ppm Se as
MSC). The differentially expressed genes included prothy-
mosin α, YB1 (Y box protein), the murine homologue of
Drosophila single-minded gene (mSim), apolipoprotein E,
and osteopontin  (OPN).  Prothymosin  α is an acce pte d
marker of tumor prognosis [11]. YB1 is a key regulator for
P-glycoprotein expression [12] and can predict drug resist-
ance and patient outcome in breast cancer [13]. mSim is
expressed in the ventral diencephalon, branchial arches,
and limbs, and its function might assist in finding the cause
of Down syndrome [14]. Apolipoprotein E has an important
role in lipid metabolism by serving as a ligand to hepatic
lipoprotein receptors [15]. OPN  is a secreted RGD
(arginine–glycine–aspartic acid)-containing phosphopro-
tein that interacts with the αvβ3 integrin and is capable of
promoting cell attachment, regulating intracellular Ca2+ lev-
els, and influencing gene expression [16]. OPN  is
expressed at higher levels in various transformed cell lines
than in their non-tumorigenic cell counterparts [17]. It has
been associated with aggravated malignancy in breast can-
cer but its functional role in this context is poorly under-
stood. In the present study we examined the efficacy of
MSC against TM6 mouse hyperplastic outgrowth and the
effect of MSC on the newly discovered in vivo target.
Methods
TM6 hyperplasia model in Balb/c mice
Twenty female Balb/c mice (3 weeks of age) were trans-
planted with TM6 hyperplastic outgrowth (TM6-HOG) in
both cleared inguinal (no. 4) mammary fat pads [18]. Two
weeks later, these mice were set up as two subgroups of
10 mice each and were fed on AIN-76A diet containing 0.1
ppm Se (nutritional level, basal diet) and 3 ppm Se in the
form of MSC (CH3-Se-CH2-CH(NH2)-COOH; Sigma, St
Louis, MO). Mammary fat pads were collected 4 and 12
weeks after transplantation, and the whole mounts were
examined for TM6-HOG growth spread. In addition, the
proliferative index of the fat pads was assessed and apop-
tosis was measured by caspase-3 activity. To assess TM6-
induced tumor incidence, 26 female Balb/c mice were
transplanted with TM6-HOG; 2 weeks later they were
divided into two equal groups and fed on diets containing
0.1 and 3 ppm Se, respectively, as described above. The
mice were palpated weekly for tumors for 23 weeks after
transplantation. Some of these tumors were subjected to
cDNA array analysis.
Bromodeoxyuridine labeling and proliferative index
Bromodeoxyuridine (BrdU; Sigma) was injected intraperito-
neally into mice (70 mg per kg body weight) 2 hours before
being killed at 4 and 12 weeks after transplantation. The
mammary fat pads were harvested, flattened, fixed in 4%
paraformaldehyde for 1 hour, and post-fixed in 70% etha-
nol. Paraffin-embedded tissues were cut (4–5 µm), then
stained with hematoxylin–eosin for histology; sections were
used for BrdU staining. The BrdU-labeling index for each
group was determined [19] by immunohistochemistry with
a cell proliferation kit (Amersham, Little Chalfont, UK). A
total of 500 cells were counted for each mammary fat pad
in each group and the proliferative index was calculated as
the percentage of positive cells. A total of three fat pads
were analyzed for each group at each time point.
Colorimetric assay for caspase-3
Mammary fat pads from each group of mice were homoge-
nized in lysis buffer (10 mM Tris-HCl [pH 7.5], 200 mM
NaCl, 1% Triton X-100, 1 mM oxidized glutathione, 5 mM
EDTA) on ice for 30 min. Lysates were centrifuged at
10,000 rpm (9300 × g) for 10 min and the supernatant was
used for the caspase-3 assay [9]. Four mammary fat pads
were pooled for each group of the Se-fed animals 4 and 12
weeks after transplantation, and this assay too was per-
formed in triplicate.
cDNA array analysis
TM6 tumor tissues from mice fed with 0.1 or 3 ppm Se
were compared for altered gene expressions after hybridi-
zation with individual membranes spotted with 1176
unique cDNA fragments (Atlas™ Mouse 1.2 Array; Clon-
tech, Palo Alto, CA) as described previously [20]. After
densitometric analysis (Molecular Dynamics, Sunnyvale,
CA) the signals were quantified and the values were nor-
malized to ubiquitin (housekeeping gene) expression levels.
Cell culture and treatment
TM6 cells were grown in 100 mm dishes for 48 hours in
Dulbecco's modified Eagle's medium (DMEM)/F12
medium supplemented with insulin (5 µg/ml), epidermal
growth factor (5 ng/ml), adult bovine serum (2%), and anti-
biotic–antimycotic solution (1×) at 37°C in the presence of
5% CO2 in air [8]. The cells were starved for 24 hours in
DMEM/F12 medium without growth factors and serum.
The cells were then treated with MSC (100 µM) for 1 hour
or 24 hours in serum-free condition, followed by 1 hour of
stimulation with growth factors and serum. RNAs from
these cells were isolated by using TRIzol (Life Technolo-
gies, Gaithersburg, MD) and reverse transcription–
polymerase chain reaction (RT–PCR) was performed for
OPN and β-actin as described below.Available online http://breast-cancer-research.com/content/6/5/R586
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RT–PCR and probing
Total RNAs from tumors of mice fed with 0.1 or 3 ppm Se
diet, along with MSC-treated cells in vitro were isolated
with the use of TRIzol. A 305 base pair PCR product for
OPN was obtained with the forward primer 5'-CTT TCA
CTC CAA TCG TCC CTA C-3' and the reverse primer 5'-
GCT CTC TTT GGA ATG CTC AAG T-3'. To normalize the
expression of OPN, a 568 base pair PCR product for β-
actin was generated from the same reverse transcription
with the forward primer 5'-GAG AAG ATC TGG CAC CAC
ACC T-3' and the reverse primer 5'-CAG GAT TCC ATA
CCC AAG AAG G-3'. The PCR was performed in a Perkin-
Elmer 9600 thermocycler after denaturation (95°C for 1
min 45 s), 26 cycles of a three-step cycle (95°C for 15 s,
57°C for 30 s, and 72°C for 1 min 55 s), and extension at
72°C for 10 min. For hybridization, the OPN and β-actin
PCR products were gel-purified with the Quiex II kit (Qia-
gen, Inc., Chatsworth, CA) and labeled with [α-32P]dCTP
with the Prime-a-gene kit (Promega, Madison, WI). The
PCR reactions were run on agarose gels, transferred to a
nylon membrane, and then hybridized with OPN probe,
washed, and exposed to Kodak MS film for 2 hours. The
same blot was subsequently probed with β-actin, washed,
and exposed to Kodak MS film for 2 hours. The blots were
scanned in a densitometer (Molecular Dynamics) and the
values for OPN were normalized to the corresponding β-
actin levels.
Migration assay
TM6 cells were grown for 48 hours in 100 mm Petri dishes
in regular medium with growth factors and serum [8]. The
cells were starved for 24 hours in DMEM/F12 medium
without growth factors or serum. The cells were then
treated with MSC (100 µM) for 1 hour or 24 hours in
serum-free condition. These pretreated cells were removed
from each dish along with the untreated control cells, and
50,000 viable cells were transferred to 8 µm pore size tran-
swell chambers (Costar, Cambridge, MA), in triplicate. The
chambers had previously been coated with gelatin (6 mg/
ml) on the inner side of the filters and rehydrated with 100
µl of DMEM/F12 medium. These chambers were placed in
a 12-well plate. The cells were allowed to settle for 1 hour
and the growth medium, along with serum and 100 µM
MSC, was added to the wells on the outside of the tran-
swell over a period of 10 hours. The culture medium was
aspirated from the inside of the transwell and the filter was
wiped clean with a cotton swab. The outer side of the mem-
brane was fixed in 1% glutaraldehyde for 1 hour. After rins-
ing the glutaraldehyde solution, the filter was stained in
hematoxylin for 10 min. Filters were subsequently washed
in water and the blue color was enhanced in saturated lith-
ium carbonate solution for 5 s. The cells migrating through
the filter to the other side were examined microscopically
under × 10 magnification and representative areas were
counted. The number of cells was averaged from three
readings for each treatment.
Statistical analysis
All statistical analyses used SigmaPlot 8.0 software. Com-
parison of numerical data was achieved with a two-tailed
unpaired t-test; P < 0.05 was considered significant.
Results
Measurement of the TM6 hyperplastic growth spread in
whole mounts of mammary fat pads 4 weeks after trans-
plantation revealed that there was no differential effect
between the two groups of mice fed with 0.1 ppm Se and
with 3 ppm Se (Table 1). However, by 12 weeks there was
a significant decrease (P < 0.05) in the spread of TM6
growth in the 3 ppm Se group in comparison with the
growth in mammary fat pads of mice fed on the basal diet.
Table 1
Effect of Se-methylselenocysteine on proliferation and apoptosis in TM6-HOG transplanted into mammary fat pads
Parameter Time of measurement (weeks) Se concentration (ppm)
0.1 3
Growth in fat pad 4 5.50 ± 1.04 5.25 ± 0.85
12 13.75 ± 1.25 8.13 ± 1.88a
BrdU labeling index 4 8.62 ± 2.34 7.00 ± 0.64
12 1.47 ± 1.01 1.27 ± 0.24
Caspase-3 activity 4 0.08 ± 0.01 0.09 ± 0.01
12 0.06 ± 0.01 0.38 ± 0.01b
Growth in fat pad was measured as the length of spread between lymph nodes in millimeters; bromodeoxyuridine (BrdU) labeling index was 
expressed as the percentage cells positive; caspase-3 activity was determined as A405. Results are means ± SEM for three or four observations. 
Student's t-test was performed to compare values between the 3 ppm Se and 0.1 ppm Se groups for each parameter. aP < 0.05; bP < 0.0001.Breast Cancer Research    Vol 6 No 5    Unni et al.
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The BrdU labeling index, indicative of proliferation in cells,
is directly related to the number of cells in S phase. We
found that 4 weeks after transplantation the labeling was
high; it then decreased by 12 weeks. There was no
significant difference between the 0.1 and 3 ppm Se
groups at either time point (Table 1). Furthermore, 12
weeks after transplantation, selenium-induced caspase-3
activity in the mammary fat pads of mice fed on 3 ppm Se
diet was elevated more than sixfold in comparison with that
in mice fed with 0.1 ppm Se (P < 0.0001) (Table 1).
The first appearance of palpable tumors was delayed by 2
weeks in the 3 ppm Se group in comparison with mice fed
on the 0.1 ppm Se diet (Fig. 1). Twenty-three weeks after
transplantation, all female Balb/c mice fed on the 0.1 ppm
Se diet developed mammary tumors, whereas only 77% of
mice fed with 3 ppm Se produced tumors in the same
period. The total number of tumors in mice in the 0.1 ppm
Se group (22 of 26 fat pads) decreased to 16 of 26 fat
pads in the 3 ppm Se group (P > 0.05). However, the aver-
age tumor size in the 3 ppm Se group (0.69 ± 0.19 cm2)
was smaller than that in the 0.1 ppm Se group (0.93 ± 0.43
cm2).
The cDNA array analysis of the tumors from both treatment
groups revealed several differentially expressed genes. The
mSim  transcription factor was upregulated more than
eightfold in the 3 ppm Se group compared with the 0.1
ppm Se group (B2h; Fig. 2a). Genes upregulated in the 0.1
ppm Se group included prothymosin  α (B12f; 1.4-fold
increase; Fig. 2a), apolipoprotein E (C2j; 1.45-fold
increase; Fig. 2a), YB1 DNA-binding protein (B7i; 1.4-fold
increase; Fig. 2a) and OPN (B13b; 14.3-fold increase; Fig.
2a). For the present study, we further analyzed the effects
of MSC on OPN in vivo and in vitro.
OPN expression in the TM6 tumor was elevated more than
14-fold compared with its level in TM6-HOG tissue (Fig.
2b, left panel). TM6 tumors in the 3 ppm Se group demon-
strated a markedly decreased expression of OPN (Fig. 2b,
right panel) vis-à-vis those in the 0.1 ppm Se group. The
average OPN expression in a set of three TM6 tumors in
the 3 ppm Se group was 2.84 (± 0.17)-fold lower than that
in the tumors from the control (0.1 ppm Se) group when
normalized with β-actin expression.
In view of the observation that OPN is related to cell spread
and motility [21], we examined the effect of Se on OPN
expression levels and cell invasion in vitro. After stimulation
with growth factors and serum, OPN expression in the TM6
tumor cells growing in vitro increased more than ninefold
Figure 1
TM6 mouse mammary tumor incidence following supplementation with  Se-methylselenocysteine (MSC) TM6 mouse mammary tumor incidence following supplementation with 
Se-methylselenocysteine (MSC). The latency period for tumor appear-
ance in the 3 ppm Se group was delayed by 2 weeks compared with 
the first tumor appearance in the 0.1 ppm Se group animals. At the end 
of 23 weeks, 0.1 ppm Se group had tumors in 22 of 26 mammary fat 
pads compared with tumors in 16 of 26 mammary fat pads in mice fed 
on the 3 ppm Se-diet.
Figure 2
cDNA array analysis of mammary tumors and osteopontin gene  expression cDNA array analysis of mammary tumors and osteopontin gene expres-
sion. (a) The section of the Atlas™ Mouse 1.2 Array (Clontech, Chats-
worth, CA) showing the differential expression of several genes in 
mammary fat pads transplanted with TM6-HOG and fed with 0.1 and 3 
ppm Se in their diet. B2h, mSim transcription factor; B7i, YB1 DNA-
binding protein; B12f, prothymosin α ; B13b, osteopontin (OPN); C2j, 
apolipoprotein E; G11, ubiquitin (housekeeping gene for normaliza-
tion). (b) Representative hybridization of reverse transcription–polymer-
ase chain reaction (RT–PCR) bands from mammary fat pads of mice 
transplanted with TM6-HOG and fed with 0.1 and 3 ppm Se in their 
diet that were probed with an OPN probe followed by a β-actin probe. 
The expression of OPN was 14-fold higher in the TM6 tumor than in 
TM6-HOG (left panel) and was decreased 3.85-fold by the high sele-
nium diet (right panel). The actin levels were similar, indicating equiva-
lent input for RNA in the assay. The negative controls for the RT–PCR 
were reactions without reverse transcriptase (–RT) during first-strand 
synthesis of cDNA.Available online http://breast-cancer-research.com/content/6/5/R586
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compared with its level in the unstimulated TM6 cells (Fig.
3). A 24-hour treatment with 100 µM MSC followed by
growth factor and serum stimulation downregulated OPN
expression 4.4-fold compared with the OPN level in TM6
cells after 1 hour of stimulation with growth factor, as seen
by RT–PCR bands and hybridized blots (Fig. 3).
Pretreatment with 100 µM MSC for 24 hours significantly
(P < 0.0001) inhibited TM6 cell migration in vitro com-
pared with control untreated cells (Fig. 4). The earliest
inhibition by MSC was observed after only 1 hour of pre-
treatment (P < 0.0001).
Discussion
MSC inhibits TM6 cell growth at the hyperplastic and tumor
stages in the mouse mammary model. A significant
decrease in growth spread of TM6 hyperplasia in mouse
mammary fat pads at 12 weeks after transplantation might
have been due to elevated caspase-3 activity in the 3 ppm
Se group. However, this growth inhibition was not associ-
ated with decreased BrdU incorporation. The lack of sup-
pression of proliferation is indicative of a possible delay of
mammary tumorigenesis by pathways that might not involve
cell growth inhibition as a primary response, as also sug-
gested by another report [4]. To our knowledge, the
present study shows for the first time that selenium can
activate caspase-3 in vivo. This finding is supported by
other reports demonstrating apoptosis in mammary tumors
in vivo [22,23] as well as in the surrounding vasculature
[24]. Further work is needed to understand the mecha-
nism(s) by which MSC induces cell death in pre-neoplastic
lesions in vivo, particularly the crosstalk between the sign-
aling molecules of the proliferative and apoptotic pathways.
The first appearance of palpable tumors in the present
study was delayed by 2 weeks in the 3 ppm Se group in
comparison with mice fed on the 0.1 ppm Se diet. Further-
more, there was a 23% inhibition in tumor incidence in the
3 ppm Se group. These data are in agreement with previ-
ous studies [25,26] showing that later stages of mouse
mammary tumorigenesis (pre-neoplastic to neoplastic
transformation of tumor growth) are not as sensitive to sele-
nium-mediated inhibition as the early stages (expression of
mammary pre-neoplastic lesions). The degree of inhibition
in tumor formation by MSC in our mouse model was mod-
est compared with that demonstrated in chemical carcino-
gen-induced rat mammary tumor models [3,4]. This
difference might be related to MSC-mediated inhibition at
initiation (carcinogen metabolism and DNA adduct forma-
tion) and promotion (proliferation and apoptosis) stages
and/or the species of animals examined.
The mammary tumors in the 3 ppm Se group were smaller
than those of the 0.1 ppm Se group, and the comparative
cDNA array analysis of these tumors revealed several differ-
entially expressed genes. To our knowledge, this is the first
report of OPN  expression being downregulated by any
selenium compound. In the present study, the TM6-HOG
tissue was compared with that of the TM6 tumor for OPN
Figure 3
Osteopontin (OPN) gene expression in vitro Osteopontin (OPN) gene expression in vitro. TM6 cells were starved 
for 24 hours before stimulation for 1 hour with growth factors (GF). A 
ninefold increase was noted in OPN expression within 1 hour of stimu-
lation compared with the OPN level in starved cells. When the starved 
cells were treated with Se-methylselenocysteine (MSC) for either 1 
hour or 24 hours before stimulation with GF, the expression of OPN 
was decreased 0.2-fold and 4.4-fold respectively compared with the 1-
hour-stimulated OPN level in the starved cells. The fold change was 
normalized with β-actin levels in the corresponding lanes.
Figure 4
MSC inhibits TM6 cell migration in vitro MSC inhibits TM6 cell migration in vitro. Pretreatment of TM6 cells with 
Se-methylselenocysteine (MSC) for 1 hour and 24 hours before stimu-
lation with growth factors (GF) and serum decreased the numbers of 
cells migrating by 44.6% and 57.6%, respectively, to the other end of 
the membrane in a transwell migration assay. Bar graphs represent the 
mean of four counts from each of the three separate wells. Error bars 
are SEM. The inhibition in migration was statistically significant at P < 
0.0001 for both pretreatments compared with controls. Only one or 
two cells were able to migrate in the absence of growth factors.Breast Cancer Research    Vol 6 No 5    Unni et al.
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expression, which was elevated more than 14-fold. This dif-
ference could not be attributed to tissue heterogeneity in
the TM6 outgrowth, because mammary epithelial cells
comprise the vast majority of the source of RNA (more than
60%). OPN is expressed at higher levels in various trans-
formed cell lines than in their non-tumorigenic cell
counterparts [17]. It has been associated with greater
malignancy in breast cancer but its functional role in this
process is poorly understood. OPN transcripts can be
detected in both invasive and in situ carcinoma compo-
nents of human breast cancer. However, the transcripts are
not detected in surrounding stromal cells or in peritumoral
macrophages [27]. The fact that treatment with 3 ppm Se
in the form of MSC decreases OPN expression in vivo
might be contributing to the smaller size of tumors
observed in our study. The contribution that OPN makes to
the development of malignancy remains obscure. Possibly
OPN promotes the development of a malignancy by stimu-
lating cellular signal transduction pathways through the
αvβ3 integrin [28]. Further experimentation will be required
to determine whether the inhibition of mammary tumors by
selenium involves this integrin. An earlier report suggested
that the ability to produce OPN does indeed contribute to
the metastatic potential of cells [29]. We have also
observed that the OPN  expression in a TM40D mouse
mammary model that has the potential to form metastasis is
significantly lowered by a 3 ppm Se diet (Emmanual Unni,
Frances S Kittrell and Raghu Sinha, unpublished data).
Both the toxicity and the chemopreventive efficacy of a
selenium compound are mainly expressed as a function of
its dose and the chemical form [30]. MSC is a stable
selenoamino acid that is capable of generating
methylselenol endogenously through the action of β-lyase
or related lyases [31]. Because the cells in culture have low
levels of β-lyase, leading to inefficient conversion of MSC
to methylselenol [32,33], we used a higher dose (100 µM)
of MSC for the cell migration experiment. In cell culture
experiments, doses of 50–100 µM MSC have been shown
to inhibit mouse mammary epithelial tumor cell growth
effectively [4,8]. Our data demonstrating a decline of OPN
expression after 24 hours of treatment with MSC is sug-
gestive of a role for selenium in the attachment and migra-
tion of TM6 cells in vitro. Future experiments will examine a
range of MSC concentrations, including the physiological
dose of 5 µM.
Considerable evidence indicates that αvβ3 integrin is impor-
tant in cell motility and can mediate attachment to various
adhesive substrates [34]. We have shown earlier that sele-
nium alters the gene expression of integrin-β and laminin
receptor-1  in TM6 cells [20]. To elucidate whether
selenium is important in αvβ3 integrin-mediated migration
inhibitions of TM6 cells will need further experimentation.
In summary, these studies show that MSC can affect TM6
cell growth at the preneoplastic and malignant growth
stages. One mediator is a lower expression of OPN and the
other is activated caspase-3. Further experimentation is
required to define the role of OPN in the inhibition of mam-
mary tumorigenesis by selenium.
Conclusions
We have analyzed OPN expression in TM6 tumors of mice
fed on a 0.1 or 3 ppm Se diet. Lowered levels of OPN in
tumors of mice fed with high selenium in their diet suggest
that this gene might have a role in the selenium-induced
inhibition of mammary growth. Similarly, lowered OPN
expression and decreased migration of TM6 tumor cells
after treatment with MSC indicate a possible role of OPN
in selenium-induced inhibition in vitro. Furthermore, cas-
pase-3 activation in fat pads of mice fed on a high selenium
diet might contribute to the decreased growth spread in the
mammary.
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